Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
JZL195
Cat. No.:
OB0225LY-0413
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
JZL195 is a selective amidase inhibitor used primarily to modulate endogenous cannabinoid signaling.
Synonym:
1210004-12-8; JZL 195; JZL-195; (4-Nitrophenyl) 4-[(3-phenoxyphenyl)methyl]piperazine-1-carboxylate; 4-Nitrophenyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate; 4-Nitrophenyl 4-(3-phenoxybenzyl)-1-piperazinecarboxylate; 1-Piperazinecarboxylic acid, 4-[(3-phenoxyphenyl)methyl]-, 4-nitrophenyl ester
CAS No.:
1210004-12-8
Compound CID:
46232606
Formula:
C24H23N3O5
Formula Weight:
433.46
Specification
Relative Density:
1.303 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
JZL195 can be used to study its potential effects on pain and neuroprotection.
Library Information
Targets:
Metabolism enzymes
Receptors:
FAAH; MAGL
Pathways:
Autophagy; Metabolism; Neuronal signaling
Plate Number:
AOCL-6
Plate Location:
c9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
11 mg/mL; 25.38 mM
ALogP:
4.794
HBA_Count:
3
HBD_Count:
0
Rotatable Bond:
7
